In the phase III of the EMILIA trail, T-DM1 significantly prolonged progression-free and overall survival with less toxicity than the dual tyrosine kinase inhibitor lapatinib plus capecitabine in patients with HER-2 positive advanced breast cancer [13]. Here, ERBB2 is linked to breast cancer.